Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01863550 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1087

Enrollment

NETWORK

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
DRUG: Carfilzomib
DRUG: Dexamethasone
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
OTHER: Quality-of-Life Assessment

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

[object Object]